Management of type 2 diabetes mellitus and cardiovascular risk -: Lessons from intervention trials

被引:34
|
作者
Yki-Järvinen, H [1 ]
机构
[1] Univ Helsinki, Dept Med, Helsinki 00029, Finland
关键词
D O I
10.2165/00003495-200060050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral Vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications,is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 50 条
  • [41] Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus
    Brownrigg, Jack R. W.
    de Lusignan, Simon
    McGovern, Andrew
    Hughes, Cian
    Thompson, Matthew M.
    Ray, Kausik K.
    Hinchliffe, Robert J.
    HEART, 2014, 100 (23) : 1837 - +
  • [42] Prevention of cardiovascular risk in patients with type 2 diabetes mellitus with aspirin
    Duly-Bouhanick, B
    Menard, S
    Hadjadj, S
    Soares-Barbosa, S
    Plun-Favreau, J
    Guilloteau, G
    PRESSE MEDICALE, 2001, 30 (02): : 87 - 91
  • [43] Risk Factors and cardiovascular Outcomes in Patients with type 2 Diabetes Mellitus
    Pavlicek, Vojtech
    DIABETOLOGE, 2018, 14 (07): : 499 - 500
  • [44] Predictor for cardiovascular risk in patients with type-2 diabetes mellitus
    Azharuddin, Md
    Kapur, Prem
    Mishra, Ritu
    Saleem, Shakir
    Gupta, Ashok Kumar
    Adil, Mohammad
    Sharma, Manju
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 12
  • [45] Acetylcarnitine Is Associated With Cardiovascular Disease Risk in Type 2 Diabetes Mellitus
    Zhao, Shuo
    Liu, Ming-Li
    Huang, Bing
    Zhao, Fu-Rong
    Li, Ying
    Cui, Xue-Ting
    Lin, Rong
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [46] Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials
    G Jerums
    S Panagiotopoulos
    E Ekinci
    R J MacIsaac
    Journal of Human Hypertension, 2015, 29 : 473 - 477
  • [47] Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials
    Jerums, G.
    Panagiotopoulos, S.
    Ekinci, E.
    MacIsaac, R. J.
    JOURNAL OF HUMAN HYPERTENSION, 2015, 29 (08) : 473 - 477
  • [48] ASSESSMENT OF CARDIOVASCULAR DISEASES RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Jose, C.
    VALUE IN HEALTH, 2017, 20 (05) : A351 - A351
  • [49] Type 2 diabetes mellitus in adolescence: Lipid and cardiovascular risk factors
    Kenneth Lee Jones
    Asheesh Kumar Dewan
    Current Diabetes Reports, 2003, 3 (3) : 255 - 262
  • [50] The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus
    van der Leeuw, J.
    van Dieren, S.
    Beulens, J. W. J.
    Boeing, H.
    Spijkerman, A. M. W.
    van der Graaf, Y.
    van der A, D. L.
    Noethlings, U.
    Visseren, F. L. J.
    Rutten, G. E. H. M.
    Moons, K. G. M.
    van der Schouw, Y. T.
    Peelen, L. M.
    HEART, 2015, 101 (03) : 222 - 229